Ashley Bedi, DO
Physical Medicine & Rehabilitation · Lodi, CANPI 1770076994
Payments from drug & device makers
Across 35 payments — averaging $28.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$160
- Merz Pharmaceuticals, LLC$147
- AbbVie$141
- Livanova USA, Inc.$68
- Johnson & Johnson$60
- Argenx US, Inc.$57
- plus $348 from 12 others
What the payments were for
- Food & beverage$982100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 5 | $160 |
| Merz Pharmaceuticals, LLC | 2 | $147 |
| AbbVie | 7 | $141 |
| Livanova USA, Inc. | 1 | $68 |
| Johnson & Johnson | 2 | $60 |
| Argenx US, Inc. | 2 | $57 |
| Otsuka America Pharmaceutical, Inc. | 2 | $51 |
| Amneal Pharmaceuticals LLC | 2 | $43 |
| Eisai Inc. | 2 | $41 |
| Biogen | 2 | $41 |
| Tanabe Pharma America, Inc. | 1 | $30 |
| Lundbeck LLC | 1 | $27 |
| ANI Pharmaceuticals, Inc. | 1 | $26 |
| Lilly USA, LLC | 1 | $22 |
| Azurity Pharmaceuticals, Inc. | 1 | $21 |
| Genentech USA, Inc. | 1 | $17 |
| AstraZeneca | 1 | $14 |
| Microtransponder, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- INBRIJA$125
How this compares
$982 in reported general payments places this provider in the 75th percentile of 830 physical medicine & rehabilitation providers in California.
See all physical medicine & rehabilitation providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Baclofen | 100 | $2,762 |
| Dantrolene Sodium | 14 | $1,586 |
| Tizanidine Hcl | 35 | $424 |
| Gabapentin | 21 | $371 |
| Cyclobenzaprine Hcl | 13 | $125 |
| Pregabalin | 13 | $68 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Lodi
- Ziyad AyyoubParamount$1.8M
- John ShenFontana$1.3M
- Andrew SkalskySan Diego$463K
- Nanette JoyceSacramento$237K
- Mary OatesSanta Maria$158K
- Jeryl WiensFresno$125K
- Pratik GandhiAnaheim$122K
- Ronald SchillingLong Beach$113K
- Kevin BarretteSan Francisco$84K
- Jeffrey ChenSan Diego$82K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.